ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Tsumura & Co.

Business Summary

Tsumura & Co. engages in the manufacture and sale of pharmaceutical products. It manufactures and sells Kampo medicine, a traditional form of medicine in Japan. It is also involved in the procurement, production, processing, and storage of botanical raw materials; production and sale of Kampo extract intermediates; and provision of logistics, storage, distribution, and materials handling services. Its products include Chujoto, L'amour, Tsumura-Kampo Kakkonto, Tsumura-Kampo Otsujito, and Tsumura-Kampo Orengedokuto. The company was founded by Jusha Tsumura on April 10, 1893 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue130,881M1,234.05M
Gross Profit74,932M706.52M
Operating income19,384M182.76M
Income before tax20,456M192.87M
Net income15,332M144.56M
EBITDA27,999M263.99M
Diluted EPS200.391.88
Dividends Per Share640.60
Total Assets319,063M2,887.44M
Total liabilities85,892M777.30M
Total equity217,787M1,970.92M
Operating cash flow16,102M151.82M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 114,957M 117,882M 120,906M 123,248M 130,881M
Gross Profit 65,500M 68,275M 71,456M 72,500M 74,932M
Operating income 15,984M 17,051M 18,521M 18,877M 19,384M
Income before tax 17,184M 20,284M 19,897M 19,223M 20,456M
Net income 12,489M 14,505M 14,594M 13,765M 15,332M
EBITDA 21,613M 23,208M 24,883M 25,283M 27,999M
Diluted EPS 179.44 200.54 190.86 179.96 200.39
Dividends Per Share 64 64 64 64 64
Total Assets 222,008M 292,379M 287,322M 313,537M 319,063M
Total liabilities 64,608M 95,845M 81,178M 99,537M 85,892M
Total equity 154,784M 193,600M 201,817M 205,378M 217,787M
Operating cash flow 21,065M 21,066M 5,450M 18,191M 16,102M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 1,061.59M 1,063.60M 1,090.27M 1,133.56M 1,234.05M
Gross Profit 604.87M 616.02M 644.35M 666.81M 706.52M
Operating income 147.60M 153.84M 167.01M 173.62M 182.76M
Income before tax 158.68M 183.01M 179.42M 176.80M 192.87M
Net income 115.33M 130.87M 131.60M 126.60M 144.56M
EBITDA 199.58M 209.39M 224.38M 232.53M 263.99M
Diluted EPS 1.65 1.80 1.72 1.65 1.88
Dividends Per Share 0.59 0.57 0.57 0.58 0.60
Total Assets 1,992.35M 2,749.21M 2,595.85M 2,904.33M 2,887.44M
Total liabilities 579.80M 901.22M 733.41M 922.02M 777.30M
Total equity 1,389.06M 1,820.40M 1,823.34M 1,902.44M 1,970.92M
Operating cash flow 194.52M 190.07M 49.14M 167.31M 151.82M

Valuation Measures

Mar 2021
PER19.73
ROA4.84%
ROE7.24%
Operating margin14.81%
Profit margin11.71%

Key executives

  • President, CEO & Representative Director: Terukazu Kato
  • COO, Director & Managing Executive Officer: Shin Adachi
  • CFO, Director & Managing Executive Officer: Muneki Handa
  • Executive Officer, GM-Kampo Research & Development: Akito Imada
  • Executive Officer, Manager-Legal & Compliance: Hiroshi Hoshi

Shareholders

  • Invesco Asset Management (Japan) Ltd. (11.9%)
  • Ping An Insurance (Group) Co. of China Ltd. (9.9%)
  • Marathon Asset Management Ltd. (6.0%)
  • Mitsubishi UFJ Financial Group, Inc. (3.5%)
  • Nikko Asset Management Co., Ltd. (3.2%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.1%)
  • Baillie Gifford & Co. (2.6%)
  • Nomura Asset Management Co., Ltd. (2.6%)
  • Tsumura & Co. Employee Stock Ownership Plan (2.3%)
  • Bright Ride Ltd. (2.2%)

Contact Details

Related Companies

  • Pingcun (Shenzhen) Medical Ltd.
  • Ping An Tsumura Co., Ltd.
  • Tsumura Board Incentive Plan
  • Shenzhen Tsumura Medicine Co., Ltd.
  • Shanghai Tsumura Pharmaceuticals Co., Ltd.
  • Logitem Tsumura KK
  • Tsumura USA, Inc.
  • Tsumura & Co. Employee Stock Ownership Plan

Competitors

    Last Updated on 22 Oct, 2021

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Try 1 month for $0.99

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends October 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to Nikkei Asia has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more